HALEY SZCZEPANIK: Open Payments
NPI 1710330576 · GLOVERSVILLE, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,066 in 56 payments from 11 companies in 2025. Trend: 2023 $438 · 2024 $1,356 · 2025 $1,066
Food & beverage: $1,060Education: $7
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 11 | $244 |
| ABBVIE INC. | 11 | $242 |
| Otsuka America Pharmaceutical, Inc. | 13 | $149 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $103 |
| GlaxoSmithKline, LLC. | 4 | $72 |
| Amgen Inc. | 3 | $60 |
| Lilly USA, LLC | 2 | $47 |
| SHIELD THERAPEUTICS INC | 2 | $47 |
| Axsome Therapeutics, Inc. | 2 | $44 |
| Novo Nordisk Inc | 2 | $36 |
Products named: AIRSUPRA, REXULTI, VRAYLAR, CAPLYTA, UBRELVY, TRELEGY ELLIPTA, ACCRUFER, OTEZLA.
Industry payments across NY — which companies pay providers there.
